^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-A2102

    i
    Other names: SHR-A2102, SHRA2102, SHR A2102
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, Nectin-4-targeted antibody-drug conjugate
    Related drugs:
    3d
    SHR-A2102-212: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=300, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tagrisso (osimertinib) • carboplatin • paclitaxel • SHR-A2102 • AiRuiLi (adebrelimab)
    16d
    Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects (clinicaltrials.gov)
    P2, N=200, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • SHR-A2102 • AiRuiLi (adebrelimab)
    17d
    A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P2 trial
    |
    Tagrisso (osimertinib) • carboplatin • paclitaxel • SHR-A2102 • AiRuiLi (adebrelimab)
    1m
    Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules. (PubMed, Front Mol Med)
    Enfortumab vedotin is an NECTIN4-targeting antibody-drug conjugate that is approved for the treatment of urothelial cancer, whereas other ADCs or derivatives that target NECTIN4, such as bulumtatug fuvedotin, SHR-A2102 and zelenectide pevedotin, are being studied in randomized phase III clinical trials. In contrast, arcotatug tavatecan, garetatug rezetecan, sonesitatug vedotin and tecotabart vedotin are anti-CLDN18.2 ADCs in phase III clinical trials for the treatment of CLDN18.2-positive gastric or gastroesophageal junction adenocarcinomas, and raludotatug deruxtecan is an anti-CDH6 ADC in a phase II/III clinical trial for the treatment of platinum-resistant ovarian cancer. ADCs that target cell-cell adhesion molecules are a rapidly emerging class of cancer therapeutics, and bispecific ADCs and longitudinal companion diagnostics are emerging to further improve the clinical benefits of conventional ADCs.
    Review • Journal
    |
    CLDN18 (Claudin 18) • CLDN6 (Claudin 6) • CDH6 (Cadherin 6) • CDH17 (Cadherin 17)
    |
    CLDN18.2 positive
    |
    Padcev (enfortumab vedotin-ejfv) • sonesitatug vedotin (AZD0901) • tecotabart vedotin (LM-302) • zelenectide pevedotin (BT8009) • SHR-A2102 • arcotatug tavatecan (IBI-343) • bulumtatug fuvedotin (9MW2821) • garetatug rezetecan (SHR-A1904) • raludotatug deruxtecan (DS-6000)
    3ms
    Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • SHR-A2102 • AiRuiLi (adebrelimab)
    4ms
    A study on the treatment of high-risk non-muscle-invasive bladder cancer with antibody-drug conjugate intravesical perfusion (ChiCTR2500106965)
    P1/2, N=42, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New P1/2 trial
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    SHR-A2102
    4ms
    Renaissance: Reverse Triple Negative Immune Resistant Breast Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Fudan University | N=30 --> 70 | Trial completion date: Mar 2023 --> Mar 2027 | Trial primary completion date: Dec 2022 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • AiRuiLi (adebrelimab) • HHPG-19K (mecapegfilgrastim)
    4ms
    SHR-A2102-I-102: Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=395, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    SHR-A2102
    5ms
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (clinicaltrials.gov)
    P1/2, N=96, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P1/2 trial
    |
    Erbitux (cetuximab) • SHR-A2102 • AiRuiLi (adebrelimab)
    5ms
    Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Fudan University
    New P2 trial
    |
    SHR-A2102 • AiRuiLi (adebrelimab)
    5ms
    SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Henan Cancer Hospital | Initiation date: Mar 2025 --> Jun 2025
    Trial initiation date
    |
    SHR-A2102 • AiRuiLi (adebrelimab)
    6ms
    Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) (clinicaltrials.gov)
    P2/3, N=840, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SHR-A2102 • AiRuiLi (adebrelimab)